Semorinemab
Semorinemab is a monoclonal antibody (mAb) designed for the treatment of Alzheimer's disease. It targets the tau protein, which is implicated in the pathogenesis of Alzheimer's disease. Semorinemab is being developed by Genentech, a member of the Roche Group.
Mechanism of Action[edit | edit source]
Semorinemab is an immunotherapy that targets the tau protein, a microtubule-associated protein that stabilizes microtubules in neurons. In Alzheimer's disease, tau proteins become hyperphosphorylated and form neurofibrillary tangles, which are one of the hallmark pathologies of the disease. By binding to tau, semorinemab is thought to prevent the spread of tau pathology in the brain, potentially slowing the progression of Alzheimer's disease.
Clinical Development[edit | edit source]
Semorinemab is currently undergoing clinical trials to evaluate its safety and efficacy in patients with Alzheimer's disease. The clinical development program includes several phases:
Phase I Trials[edit | edit source]
The initial phase I trials focused on assessing the safety, tolerability, and pharmacokinetics of semorinemab in healthy volunteers and patients with mild to moderate Alzheimer's disease. These studies provided preliminary data on the drug's safety profile and optimal dosing.
Phase II Trials[edit | edit source]
Phase II trials are designed to further evaluate the efficacy of semorinemab in a larger cohort of patients. These studies aim to determine the drug's impact on cognitive decline and other clinical endpoints associated with Alzheimer's disease.
Phase III Trials[edit | edit source]
Pending successful results from phase II trials, semorinemab may advance to phase III trials, which are larger and more definitive studies intended to confirm the drug's efficacy and safety in a broader patient population.
Potential Benefits and Challenges[edit | edit source]
The development of semorinemab represents a novel approach to treating Alzheimer's disease by targeting tau pathology. If successful, it could offer a new therapeutic option for patients with this debilitating condition. However, challenges remain, including the complexity of Alzheimer's disease pathology and the need for biomarkers to accurately assess treatment response.
Also see[edit | edit source]
Template:Alzheimer's disease navbox
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
